' '
Deutsch | English    

Research Database PMU-SQQUID

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
Huemer, F; Dejaco, M; Grabmer, C; Melchardt, T; Neureiter, D; Mayer, G; Egle, A; Greil, R; Weiss, L;
Wien Klin Wochenschr. 2017; 129(3-4):-144
Case Reports

PMU-Authors

Egle Alexander
Grabmer Christoph
Greil Richard
Huemer Florian
Melchardt Thomas
Neureiter Daniel
Weiss Lukas

Abstract

Hereditary hemorrhagic telangiectasia is an inherited autosomal dominant disease presenting with recurrent bleeding episodes and iron deficiency anemia due to vascular malformations. Hereditary hemorrhagic telangiectasia is associated with an increased risk of stroke, gastrointestinal bleeding and pulmonary hypertension and life expectancy is significantly reduced. Excess vascular endothelial growth factor (VEGF) plays a key role in the pathophysiology of the disease.


Useful keywords (using NLM MeSH Indexing)

Angiogenesis Inhibitors/administration*

dosage

Bevacizumab/administration*

dosage*

Dose-Response Relationship, Drug

Drug Administration Schedule

Epistaxis/diagnosis

Epistaxis/etiology

Epistaxis/prevention*

control*

Humans

Telangiectasia, Hereditary Hemorrhagic/complications

Telangiectasia, Hereditary Hemorrhagic/diagnosis*

Telangiectasia, Hereditary Hemorrhagic/drug therapy*

Treatment Outcome

Vascular Endothelial Growth Factor A/antagonists*

inhibitors


Find related publications in this database (Keywords)

VEGF
Anemia
Nosebleeds
Telangiectasia
Transfusion
Bevacizumab